Antiplatelet

Experts Teach on Anticoagulant and Antiplatelet Update

by

OSU Wexner Medical Center logo Experts Teach on Anticoagulant and Antiplatelet Update. Aspirin is now used to prevent and treat cardiovascular disease due to its antithrombotic effects. It even prevents cancer! Our understanding of Aspirin and it’s benefits and harms has advanced tremendously in recent years. We also have several new antiplatelet and anticoagulant options.

To share the latest research and guidelines for using anticoagulant and antiplatelet agents, We’ve invited two of Ohio State University’s Pharmacology experts. We are pleased to introduce Doctor of Pharmacy Alyssa Rinaldi who is the Outpatient Anticoagulation Clinic lead & Danielle Blais who is a Doctor of Pharmacy and Lead Specialty Practice Pharmacist of OSU Cardiology.

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to:

  • Re-assess historical “gray areas” for DOAC use including in obesity, mechanical heart vales, antiphospholipid syndrome (APS) mechanical heart valves, and treatment of left ventricular (LV) thrombus
  • Explore the anticoagulation pipeline including Factor XI inhibitors
  • Describe the role of aspirin and oral P2Y12 inhibitors for patients with chronic coronary disease or acute coronary syndromes with or without percutaneous coronary intervention
  • Evaluate the advantages and disadvantages of the different P2Y12
    inhibitors

You’ll also learn about the following:

  • Single Antiplatelet Therapy
  • Pre-procedure Medication recommendations

You can find this and many other MedNet21 programs on the OSU – CCME website.
Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Get Anticoagulant and Antiplatelet Update from CME Webcast

by

OSUWexnerbloglogo2014 Get Anticoagulant and Antiplatelet Update from CME Webcast. We now have many new anticoagulant and antiplatelet drugs for physicians to choose from but more choices means that it can be harder to select the best drug for any given clinical situation. On this CME webcast, we are going to help you pick the best anticoagulant and the best antiplatelet for your patients. We’re pleased to welcome two anticoagulation experts from the Ohio State University. Tiffany Ortman is a clinical pharmacist who will be updating us about anticoagulants. And Danielle Blais is also a clinical pharmacist who will be updating us about antiplatelets.

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DETERMINE optimal oral anticoagulant based on patient-specific characteristics; RECOMMENDED monitoring for direct oral anticoagulants; DESCRIBE the role of aspirin and oral P2Y12 inhibitors for patients with stable ischemic heart disease or acute coronary syndromes with or without percutaneous coronary intervention; and EVALUATE the advantages and disadvantages of the different P2Y12 inhibitors.

You’ll also learn about the following:

  • The spectrum of anticoagulants
  • New anti-platelet drugs
  • Direct oral anticoagulant costs and insurance coverage
  • Home INR monitoring

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.